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Transcriptional cascades that operate over the
course of lineage development are fundamental
mechanisms that control cellular differentiation. In
the developing central nervous system (CNS), these
mechanisms are well characterized during neuro-
genesis, but remain poorly defined during neural
stem cell commitment to the glial lineage. NFIA is
a transcription factor that plays a crucial role in the
onset of gliogenesis; we found that its induction is
regulated by the transcription factor Sox9 and that
this relationship mediates the initiation of gliogene-
sis. Subsequently, Sox9 and NFIA form a complex
and coregulate a set of genes induced after glial initi-
ation. Functional studies revealed that a subset of
these genes, Apcdd1 andMmd2, perform key migra-
tory and metabolic roles during astro-gliogenesis,
respectively. In sum, these studies delineate a tran-
scriptional regulatory cascade that operates during
the initiation of gliogenesis and identifies a unique
set of genes that regulate key aspects of astro-glial
precursor physiology during development.
INTRODUCTION
Cell fate decisions in the developing central nervous system
(CNS) are governed by transcriptional networks that control
both cellular diversity and lineage progression. These networks
operate in both space and time to control these distinct aspects
of CNS development. Spatial patterning of homeodomain-
containing (HD) transcription factors along the dorsal ventral
axis of the spinal cord is responsible for the specification of
distinct subtypes of neurons in progenitor populations (Briscoe
et al., 2000; Ericson et al., 1997; Pierani et al., 1999). Subse-
quently, these progenitor populations undergo a series of differ-entiative steps over time that culminates in the generation of
terminally differentiated neurons (Lee and Pfaff, 2003; Novitch
et al., 2001; Thaler et al., 2004). These sequential differentiative
steps are governed by temporal changes in the transcription
factor milieu; therefore, delineating transcriptional regulatory
cascades is crucial to our understanding of the development of
neural cell lineages. Although these transcriptional mechanisms
have been characterized for several neuronal subtypes in the
developing spinal cord, analogous relationships between tran-
scriptional regulators of early gliogenesis remain poorly defined
(Briscoe and Novitch, 2008; Lee et al., 2005; Thaler et al., 2002).
During embryonic development of the CNS, neural stem cells
undergo a characteristic temporal pattern of differentiation
wherein neurons are generated first followed by glial cells. This
developmental transition is best characterized in the ventral
region of the mouse and chick embryonic spinal cord, where
neurogenesis occurs between E9.5 and E11.0 in mouse (E2–E4
in chick) and gliogenesis commences at E11.5 (E5 in chick)
(Kessaris et al., 2001; Rowitch, 2004; Zhou et al., 2001). This
developmental interval, herein called the ‘‘gliogenic switch,’’
consists of two distinct molecular processes: the cessation of
neurogenesis and the initiation of gliogenesis. Importantly, while
these populations undergo a change in cell fate, neurogenic
capacity is maintained and gliogenic potential is acquired
(Mukouyama et al., 2006; Scott et al., 2010). Previously, we
used this developmental process as a model for examining the
formative stages of gliogenesis and identified nuclear factor-I
A (NFIA) as a crucial transcriptional determinant that regulates
the initiation of gliogenesis (Deneen et al., 2006). Importantly,
the de novo induction of NFIA expression in neural stem cell
populations is tightly correlated with the timing of the initiation
of gliogenesis at E11.5 in mouse (E5 in chick). Therefore, the
identification of the transcriptional processes that control the
induction of NFIA provides a starting point in defining tran-
scriptional regulatory cascades that operate in neural stem cells
during the gliogenic switch.
Another transcription factor associated with the initiation of
gliogenesis is the HMG-box family member Sox9. Genetic
knockout of Sox9 results in an extended period of neurogenesis,Neuron 74, 79–94, April 12, 2012 ª2012 Elsevier Inc. 79
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Figure 1. Sox9 Directly Regulates the Activity of the NFIA-e123 Enhancer
(A) Schematic illustrating NFIA enhancer elements. White lines are conserved regions; blue boxes the enhancer.
(B) Conservation of mouse and chick e123 sequence.
(C) Map of chick e123 enhancer. Alignment of chick and mouse Sox9-binding sites. Red box denotes region deleted in chick e123-DMu2.
(D–F) Expression of NFIA detected by immunostaining.
(G–L) Activity of e123; arrow indicates activity in the VZ and cherry is electroporation control.
(M–P) Ectopic Sox9 induces e123 activity at E4. Immunostaining for AMV (N) and HA-Sox9 (P).
(Q–V) Region 2 recapitulates activity of e123 at E6.
(W–Z) Loss of activity in DMu2-GFP at E6.
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Sox9 and NFIA Coordinate Gliogenesiscoupled with a delay in the onset of oligodendrogenesis,
a phenotype consistent with a role during the gliogenic switch
(Stolt et al., 2003). In addition, Sox9 has been implicated in initi-
ating and maintaining neural stem cell populations in the embry-
onic and adult CNS (Cheng et al., 2009; Scott et al., 2010).
Although Sox9 function has been associated with several critical
aspects of CNS development, our understanding of how it
contributes to the initiation of gliogenesis and coordinates
these diverse functions during CNS development remain unde-
fined. Thus, delineating these mechanisms will reveal new
insight into the gliogenic switch and Sox9 function during CNS
development.
To decipher the transcriptional processes that govern NFIA
induction, we performed in vivo screening of NFIA enhancer
elements. This screen identified an enhancer element that
recapitulates NFIA induction in vivo and is directly regulated by
Sox9. Subsequent studies revealed that Sox9 directly regulates
NFIA, and this relationship is crucial for the initiation of gliogen-
esis. Next we demonstrate that Sox9 and NFIA physically
associate and that this Sox9/NFIA complex directly regulates
a subset of genes induced just after the initiation of gliogenesis.
Functional studies revealed that two of these genes, Apcdd1
and Mmd2, perform key migratory and metabolic roles during
gliogenesis, respectively. In sum, these studies delineate a tran-
scriptional regulatory cascade that operates during the initiation
of gliogenesis and identifies a unique set of genes specifically
associated with astro-glial precursors that function to regulate
key aspects of their physiology during development.
RESULTS
e123 Enhancer Recapitulates NFIA Induction In Vivo
NFIA is induced in the ventricular zone (VZ) of the developing
spinal cord at the onset of gliogenesis in both chick (Figures
1D–1F) and mouse (Deneen et al., 2006). To elucidate the tran-
scriptional mechanisms that govern NFIA induction, we sought
to identify cis-acting regulatory elements by aligning 100 kb 50
of the transcriptional start site of the chick and mouse NFIA
gene. This analysis identified 12 regions between 100–500 bp
in length that share >70% identity (Figure 1A, white lines).
Next, we grouped these regions into six clusters, isolated the
putative enhancers and the surrounding 1 kb on either side
from chick genomic DNA (Figure 1A, blue boxes), and cloned
them upstream of a minimal promoter and a GFP reporter.
To determine whether these putative NFIA enhancer elements
have activity that resembles the spatial and temporal patterns of
NFIA induction, we introduced them into the embryonic chick
spinal cord via electroporation and harvested during the E4–E6
NFIA induction interval (Figures 1D–1F). Each enhancer was
coelectroporated with a CMV-cherry construct that served as
an internal control for electorporation efficiency (Figures 1J–1L).
Among six enhancer elements, e123 demonstrated activity(AA and BB) FACS quantification of experiment in (M)–(P) (AA) and (W)–(Z) (BB)
Error bars represent SD.
(CC) PCR detection of Sox9-Mu2 site in Sox9 ChIP experiment in chick and E12
Please also see Figures S1 and S2.in the VZ during the E4–E6 induction interval (Figures 1G–1I),
with the remaining enhancers demonstrating activity at time
points prior to NFIA induction or in motor neurons (Figure S1
available online). We chose to focus our attention on the e123
enhancer because its pattern of activity is strongly correlated
with endogenous NFIA induction, where it demonstrates a sharp
upregulation in VZ populations during the E4–E6 interval (Figures
1G–1I, arrows). By combining cross species genomic analysis
with in vivo enhancer screening, we have identified a NFIA
enhancer element that recapitulates its spatial and temporal
patterns of induction.
Sox9 Directly Regulates e123 Activity
To identify transcriptional regulators of e123, we used bioinfor-
matics to identify putative transcription factor binding sites
within this region and cross-correlated this analysis with an atlas
of transcription factors expressed in the VZ of the embryonic
mouse spinal cord during early gliogenesis (Fu et al., 2009).
This analysis identified several transcription factors, including
Sox9, which contain binding sites in e123 (Figures 1C and S1).
Sox9 is of particular interest because its expression is induced
prior to NFIA in the embryonic spinal cord, and genetic knockout
of Sox9 results in a delay in the onset of oligodendrocyte forma-
tion (Stolt et al., 2003). To determine whether Sox9 can induce
e123 activity, we performed coelectroporation and assessed
activation at time points prior to e123 induction (E4, see Fig-
ure 1D). As indicated in Figures 1M–1P and 1AA, ectopic expres-
sion of Sox9 is sufficient to induce precocious and ectopic
activity of e123 at E4. This activation of e123 appears to be
specific to Sox9, because Sox2 overexpression is not sufficient
to induce e123 activity at E4 (Figure S2). Deletion mapping
revealed that region 2 contains the Sox9 response site and,
importantly, can recapitulate the activity of e123 (Figures 1Q–1V
and S2). Together, our analysis reveals that Sox9 controls
e123 activity through region 2.
To determine whether the Sox9 site within region 2 of e123
(herein called Sox9-Mu2) is responsible for the activity of e123,
we deleted it in the context of the full-length e123 enhancer
and assessed activation at E6 (Figure 1C, red box). Deletion of
Sox9-Mu2 resulted in a loss of e123 activity at E6, indicating
that this site mediates e123 activity (DMu2-GFP) (Figures 1X
and 1BB). Further supporting the regulatory relationship be-
tween e123 and Sox9, coelectroporation of e123 with a domi-
nant-negative version of Sox9 (Sox9-EnR) resulted in a loss of
activity at E6 (Figure S2; Scott et al., 2010). Next, we performed
chromatin immunoprecipitation (ChIP) assays to determine
whether Sox9 directly associates with the Mu2 site in e123
region of the endogenous NFIA promoter. To this end we elec-
troporated HA-Sox9 into the embryonic chick spinal cord, har-
vested embryos at E4, and performed ChIP assays on chick
spinal cord lysates. As indicated in Figure 1CC, Sox9 is able to
specifically ChIP the Sox9-Mu2 site in the e123 enhancer offrom four independent experiments. In (AA), *p = 0.012; in (BB), *p = 0.0002.
.5 mouse spinal cord.
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Sox9 and NFIA Coordinate Gliogenesisthe NFIA promoter. Taken together, these data indicate that
Sox9 is necessary and sufficient for the activity of the e123
enhancer and does so via a direct mechanism.
NFIA Functions Downstream of Sox9 during the
Initiation of Gliogenesis
Because Sox9 directly controls e123 enhancer activity, we
reasoned that manipulation of Sox9 activity would impact
expression of NFIA. To this end we introduced a dominant
repressor form of Sox9, Sox9-EnR (Scott et al., 2010), into the
chick spinal cord and found that it inhibited the expression of
NFIA (Figure 2F). Next we introduced wild-type Sox9 or a domi-
nant activator form of Sox9, Sox9-VP16, and found that both
forms are sufficient to induce ectopic NFIA expression in regions
outside the VZ (Figures 2G, 2H, and 2P, arrows). These observa-
tions indicate that Sox9 functions as a transcriptional activator to
induce NFIA expression and are consistent with our findings that
it regulates the activity of the e123 enhancer.
In the course of analyzing the Sox9 and the Sox9-VP16 elec-
troporated embryos, we noticed that in regions outside the VZ
demonstrating ectopic NFIA expression, there was also ectopic
expression of the early astro-glial precursor marker GLAST
(Figures 2L, 2M, and 2Q, arrows; Shibata et al., 1997). This
observation indicates that Sox9 and Sox9-VP16 are sufficient
to induce ectopic expression of glial precursor markers and is
consistent with a role for Sox9 during the initiation of gliogenesis.
Given that these GLAST-expressing regions contain ectopic
NFIA and that NFIA is necessary for GLAST expression, we
next determined whether the ability of Sox9 to induce ectopic
GLAST is reliant upon its regulation of NFIA (Deneen et al.,
2006). Here, we coelectroporated Sox9-VP16 along with an
NFIA-shRNAi and examined the expression of GLAST and a
set of other astro-glial precursor markers (Figure S3). As shown
in Figures 2I, 2N, and 2Q, Sox9-VP16 is not capable of inducing
ectopic GLAST in the absence of NFIA, indicating that Sox9
regulation of NFIA results in the ectopic induction of glial
precursor markers. Next, we performed the converse experi-
ment by coelectroporating Sox9-EnR and NFIA and found that
NFIA can restore GLAST in the presence of Sox9-EnR (Figures
2J and 2O), further indicating that NFIA functions downstream
of Sox9. Collectively, these data establish a functional hierarchy
between Sox9 and NFIA during the initiation of gliogenesis,
where the ability of Sox9 to promote the initiation of gliogenesis
is linked to its direct induction of NFIA expression.
Sox9 Is Necessary for NFIA Induction
The foregoing data gathered in the embryonic chick spinal cord
indicate that Sox9 directly regulates NFIA induction and that this
relationship is crucial for the initiation of gliogenesis. We next
sought to determine whether these same regulatory relation-
ships are present in the mouse. First, we determined the
temporal patterns of Sox9 and NFIA induction and found that
Sox9 is induced prior to NFIA in the VZ of the embryonic spinal
cord (Figures 2R–2Y). Examination of the mouse e123 enhancer
revealed a Sox9 site within the conserved Sox9-Mu2 region
(Figures 1B and 1C), and therefore we next determined whether
Sox9 could ChIP this site in the e123 enhancer region within the
endogenous mouse NFIA promoter. To this end, we performed82 Neuron 74, 79–94, April 12, 2012 ª2012 Elsevier Inc.ChIP from E12.5 mouse spinal cord and found that Sox9 is
capable of interacting with the Sox9-Mu2 binding site in the
e123 enhancer of the mouse NFIA promoter (Figure 1CC). These
data suggest that Sox9 and NFIA have a similar regulatory rela-
tionship in mouse and chick.
To provide genetic evidence linking Sox9 to the induction of
NFIA during the initiation of gliogenesis, we intercrossed the
Sox9fl/fl and nestin-cre mouse lines (Akiyama et al., 2002). This
approach has been used previously to conditionally delete
Sox9 in VZ populations of the embryonic spinal cord and re-
vealed a delay in the generation of oligodendrocytes (Stolt
et al., 2003). Given the regulatory relationship between Sox9
and NFIA, we reasoned that loss of Sox9 in this context would
impact the timing and/or the expression of NFIA. To examine
this possibility, we generated E11.5–E12.5 Sox9fl/fl;nestin-cre
and Sox9fl/+;nestin-cre embryos and assessed the expression
of NFIA (Figures 2Z–2GG). NFIA is normally induced in the
VZ of the spinal cord at E11.5, but in the absence of Sox9, induc-
tion of NFIA was delayed by 1 day to E12.5 (Figures 2DD–2GG,
arrow). Analysis at E12.5 revealed reduced levels of NFIA
expression in the absence of Sox9 (Figures 2FF and 2GG, arrow).
Further analysis of these embryos revealed that the induction of
GLAST is also delayed from E11.5 to E12.5 and reduced in the
absence of Sox9 (Figures 2HH–2KK), correlating the expression
patterns of NFIA and GLAST and reinforcing the functional
hierarchy established in our chick studies. These mouse studies
provide genetic evidence that Sox9 is necessary for the induc-
tion and expression of NFIA during the initiation of gliogenesis
in the developing spinal cord.
Identification of Common Sox9 and NFIA Target Genes
Having established that the Sox9 and NFIA regulatory axis is
crucial for the initiation of gliogenesis in both the mouse and
chick spinal cord, we next sought to decipher how these tran-
scription factors operate during the next phase of gliogenesis.
Given the importance of cofactors in modulating transcription
factor activity during temporally distinct phases of development,
coupled with the observations that Sox9 and NFIA are coex-
pressed in the gliogenic VZ (see Figures 2T, 2U, 2X, and 2Y),
we hypothesized that Sox9 and NFIA physically interact and
that this interaction regulates a repertoire of genes that define
a temporally distinct phase of glial lineage development (Fig-
ure 3B). Therefore, we first examined whether there is a bio-
chemical relationship between Sox9 and NFIA by determining
whether they can physically associate. To this end, we per-
formed immunoprecipitation (IP) experiments from E12.5 mouse
spinal cord. Protein lysates from embryonic spinal cord were
immunoprecipitated with antibodies to endogenous Sox9 and
western blotted with antibodies to NFIA. The results of this IP-
western indicate that Sox9 and NFIA physically interact in the
embryonic spinal cord (Figure 3A). We confirmed this interaction
by doing IP-westerns on ectopically expressed, tagged versions
of NFIA and Sox9 in both p19 mouse embryonal carcinoma and
HEK293 cells (Figure S4).
That Sox9 and NFIA physically associate raised the possibility
that they coregulate a cohort of genes induced during the early
phases of gliogenesis (Figure 3B). To identify candidate genes
that are coregulated by Sox9 and NFIA, we utilized gene
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Figure 2. NFIA Expression Is Regulated by Sox9 in Embryonic Spinal Cord
(A–O) Sox9-EnR blocks NFIA and GLAST expression (A, F, K); Sox9 and Sox9-VP16 promote ectopic NFIA and GLAST (Sox9, B, G, L; Sox9-VP16, C, H, M);
NFIA-shRNAi blocks Sox9-VP16 induction of ectopic GLAST (N); and NFIA rescues GLAST in the presence of Sox9-EnR (J, O).
(P and Q) Quantification of the number of ectopic NFIA- and GLAST-expressing cells, from three experiments. Error bars represent SD.
(R–Y) Sox9 is induced in the VZ prior to NFIA. Immunostaining for Sox9 (R–U) and NFIA (V–Y) in the embryonic mouse spinal cord from E9.5 to E12.5.
(Z–KK) Sox9/ embryos demonstrate delayed and reduced NFIA and GLAST expression at E11.5 (EE, II) and E12.5 (GG, KK). Images presented are adjacent
sections from a single embryo; heterozygote and homozygote images are from littermates and are representative of five embryos for each condition.
Please also see Figure S3.
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Figure 3. Identification of Candidate Targets of the Sox9/NFIA Complex
(A) Sox9 and NFIA co-IP from E12.5 spinal cord extracts.
(B) Schematic illustrating the possible mode of Sox9/NFIA function during early gliogenesis.
(C) Microarray analysis reveals a set of genes induced between E11.5 and E12.5; the green bar represents the induction of Sox9 (Figures 2R–2U) and red bar the
induction of NFIA (Figures 2V–2Y).
(D) The selection criteria that resulted in the 15 candidate genes (see Experimental Procedures and Supplemental Experimental Procedures).
(E–P) In situ hybridization on E10.5–E12.5 embryonic spinal cord sections for four of the candidate genes identified in the screen. Apcdd1 is also expressed in
endothelial cells outside the VZ.
Please also see Figure S4 and Table S1.
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Sox9 and NFIA Coordinate Gliogenesisexpression profiling data we previously generated from mouse
VZ populations prospectively isolated at 24 hr intervals during
the E9.5–E12.5 developmental interval (Deneen et al., 2006;
Mukouyama et al., 2006). Because Sox9 and NFIA are coex-
pressed in the VZ from E11.5 onward, we reasoned that putative
targets of the Sox9/NFIA complex are likely to be induced
between E11.5 and E12.5. Analysis of our microarray data set
revealed a cohort of genes specifically induced during the
E11.5–E12.5 interval (Figures 3C and 3D; Table S1). Because
we are seeking to identify candidate genes coregulated by the
Sox9/NFIA complex, we used bioinformatics (see Experimental
Procedures) to identify genes that contain Sox9 and NFIA
binding sites in close proximity (i.e., 120 bp apart) within their
putative promoter region (25 kb from the transcriptional start
site). This analysis resulted in the identification of 15 candidate
genes, 8 of which demonstrated specific induction in VZ popula-
tions between E11.5 and E12.5 (Figures 3E–3P and S4). The
temporal patterns of induction of this cohort of genes indicate
that they mark a distinct phase of gliogenesis that occurs after
initiation, and, importantly, are candidate targets of the NFIA/
Sox9 complex.84 Neuron 74, 79–94, April 12, 2012 ª2012 Elsevier Inc.NFIA andSox9Coregulate Expression ofApcdd1,Mmd2,
and Zcchc24
To determine which of the eight candidate genes are regulated
by the Sox9/NFIA complex, we performed qRT-PCR on spinal
cord from E12.5 NFIA- or Sox9-deficient and heterozygote
control embryos, reasoning that those candidate genes demon-
strating reduced levels of expression in both mutants are likely
to be targets of this complex. This analysis revealed that four
of the eight genes are significantly reduced in the absence of
NFIA or Sox9: Apcdd1, Mmd2, Zcchc24, and Hod-1 (Figure 4M
and S4). Next we performed in situ hybridization on E12.5
NFIA- or Sox9-deficient and heterozygote control embryos and
confirmed the reduced levels of expression of Apcdd1, Mmd2,
and Zcchc24 (Figures 4A–4L). These data provide genetic
evidence that expression of these genes is dependent on both
NFIA and Sox9.
We next sought to determine whether Sox9 and NFIA are
capable of interacting with their binding sites in the promoter
regions of Apcdd1, Mmd2, and Zcchc24 by performing ChIP
on E12.5 spinal cord. To determine whether endogenous Sox9
and NFIA interact with their binding sites, we designed primers
Neuron
Sox9 and NFIA Coordinate Gliogenesisflanking their sites and used PCR to detect ChIP of these regions
(Figures 4N, 4P, and 4R, black arrows; Figure S5). These ChIP
assays demonstrate that NFIA and Sox9 bind regions of the
Apcdd1, Mmd2, and Zcchc24 promoters that contain their
consensus binding sites (Figures 4N, 4P, and 4R), indicating
a direct regulatory relationship.
Although the foregoing data indicate that Sox9 and NFIA can
directly regulate the expression of Apcdd1, Mmd2, and
Zcchc24, they do not distinguish between individual and collab-
orative regulation of these genes. To determine whether Sox9
and NFIA collaborate to activate Apcdd1, Mmd2, and Zcchc24
expression, we cloned their promoter regions and examined
the ability of Sox9 and NFIA to activate these regulatory
elements. Our reporter assays indicate that NFIA and Sox9 alone
are not sufficient to activate the Zcchc24 promoter, but
combined expression resulted in a 3.5-fold induction in promoter
activity (Figure 4S). Similarly, analysis of the Apcdd1 andMmd2
promoters indicated that combined expression of Sox9 and
NFIA resulted in a 4-fold increase in activity compared to indi-
vidual expression (Figures 4O and 4Q). These data indicate
that Sox9 and NFIA collaborate to drive activation of these regu-
latory elements. In parallel, we used two mutant versions of
Sox9, one that is not capable of binding DNA (Sox9-F12L) and
another that is deficient in protein dimerization (Sox9-A76E)
(Mertin et al., 1999; Sock et al., 2003). We found that for all three
promoters, combined induction is dependent upon both dimer-
ization and DNA binding, as shown by the fact that synergistic
activation with NFIA was significantly reduced with both Sox9
mutants (Figures 4O, 4Q, and 4S).
We next sought in vivo evidence for collaborative regulation of
Apcdd1, Mmd2, and Zcchc24 by Sox9 and NFIA by assessing
these regulatory relationships in the chick model. Analysis of
these genes in the chick spinal cord revealed similar expression
dynamics and regulatory relationships with both Sox9 and NFIA,
suggesting that this mechanism is conserved across species
(Figures 4T–4X and S6). Our preceding data point to a collabora-
tive model of gene activation that can be tested in the chick by
examining the ability of NFIA to rescue gene expression in the
presence of Sox9-EnR. Analysis of embryos coelectroporated
with Sox9-EnR and NFIA revealed a similar loss of Apcdd1,
Mmd2, and Zcchc24 expression compared to the Sox9-EnR
control (Figures 4T–4CC), indicating that NFIA is not capable of
restoring gene expression in the presence of Sox9-EnR. These
data suggest that fully functional Sox9 and NFIA are required
for complete expression of these genes, and in conjunction
with our genetic and biochemical data support a collaborative
model of gene regulation.
Apcdd1,Mmd2, and Zcchc24 Restore Gliogenesis in the
Absence of NFIA
Apcdd1 is a membrane-bound glycoprotein that can antagonize
Wnt signaling, Mmd2 (also known as PAQR 10) is a putative
mitochondrial protein, and Zcchc24 is a zinc finger-containing
gene that is a putative transcription factor (Go´n˜ez et al., 2008;
Shimomura et al., 2010). Because each of these genes has func-
tions associated with cellular processes that can influence cell
fate decisions, we reasoned that they participate in the early
stages of gliogenesis. Therefore, to investigate the functionalsignificance of this regulatory node within our transcriptional
hierarchy, we examined whether Apcdd1, Mmd2, or Zcchc24
can restore gliogenesis in the absence of NFIA. To perform these
experiments, we made use of the embryonic chick spinal cord
and an NFIA-shRNAi that effectively blocks the initiation of glio-
genesis (Deneen et al., 2006). In these experiments, we coelec-
troporated the NFIA-shRNAi along with a cDNA to Apcdd1,
Mmd2, or Zcchc24 in the embryonic chick spinal cord and har-
vested embryos at early gliogenic stages (E5.5). Our rescue
experiments revealed that coelectroporation of Apcdd1 or
Zcchc24 with the NFIA-shRNAi resulted in the restoration of
GLAST and FGFR3 (Figures 5M, 5N, 5R, 5S, 5Z, and 5AA) but
not Olig2 (Figures 5O, 5T, and 5BB), whereas coelectroporation
ofMmd2 resulted in rescue of GLAST, FGFR3, andOlig2 (Figures
5H–5J and 5Z–5BB). Next, we determined whether Apcdd1,
Mmd2, or Zcchc24 restore gliogenesis in the presence of
Sox9-EnR. Here we found similar results, where Apcdd1 and
Zcchc24 rescue GLAST and FGFR3, but not Olig2, whereas
Mmd2 rescues all three markers (Figure S7).
We next performed late-stage rescue to determine whether
these gene can restore subsequent stages of glial lineage devel-
opment in the absence of NFIA. In these studies we electropo-
rated each gene along with the NFIA-shRNAi, harvested at
E8.5, and assessed the number of migrating astrocyte and oligo-
dendrocyte precursors outside the VZ. Consistent with our early
stage rescue studies, we found that Acpdd1 and Zcchc24
restored migration of astrocyte precursors (ASPs) but not oligo-
dendrocyte precursors (OLPs) (Figures 5OO–5QQ, 5TT–5VV,
and 5WW–5YY), whereas Mmd2 was able to restore migration
of both ASP and OLP populations (Figures 5JJ–5LL and 5WW–
5YY). Collectively, these rescue studies indicate that the Sox9/
NFIA gene regulatory network activates multiple, independent
pathways that contribute to the specification and differentiation
of both ASP and OLP populations.
Mmd2 Is Required for Proliferation of Glial Precursors
and Energy Metabolism
The foregoing data suggest that these genes play a key role in
the specification and differentiation of glial populations; there-
fore, we next sought to understand how they function to promote
gliogenesis. To this end we performed shRNAi knockdown of
Mmd2 with an RCAS-shRNAi system. The effective knockdown
ofMmd2 at E6was verified by in situ hybridization and resulted in
decreased expression of ASP markers GLAST, FGFR3, and
FABP7 and of OLP marker Olig2 (Figures 6A–6F). Further anal-
ysis revealed a 60% decrease in the number of Pax6-express-
ing progenitors, without a significant increase in cell death as
measured by caspase 3 staining or concomitant increase in neu-
rogenesis (Figure S8). To control for the specificity of the Mmd2
knockdown phenotype, we generated a mutant version of the
Mmd2-shRNAi containing five nucleotide substitutions, which
had no effect on ASP, OLP, or Pax6 marker expression and
demonstrated similarly low levels of caspase 3 staining (Figures
6H–6M and S8). Next, to confirm that these phenotypes are due
to a loss ofMmd2, we performed a rescue experiment, where we
coelectroporated a mouse cDNA to Mmd2 with the Mmd2
shRNAi. As indicated in Figures 6O–6T, Mmd2 is able to rescue
the loss of ASP and OLP markers. Collectively, these dataNeuron 74, 79–94, April 12, 2012 ª2012 Elsevier Inc. 85
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Figure 4. Sox9 and NFIA Coregulate Apcdd1, Mmd2, and Zcchc24
(A–L) Apcdd1, Mmd2, and Zcchc24 expression is reduced in E12.5 spinal cord from Sox9/ or NFIA/ embryos.
(M) qPCR analysis frommRNA extracted from E12.5 Sox9+/ or Sox9/ and E12.5 NFIA+/ or NFIA/ embryos. Analysis for both experiments is representative
of three embryos for each genotype (*p < .004).
(N, P, R) E12.5 mouse spinal cord ChIP demonstrating that Sox9 and NFIA associate with the Apcdd1, Mmd2, and Zcchc24 promoters. Green ovals are Sox9
binding sites and red ovals are NFIA binding sites.
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Figure 5. Apcdd1, Mmd2, and Zcchc24 Rescue NFIA Knockdown in Chick
(A–E) NFIA-shRNAi + RCAS control results in loss of glial markers in the chick at E5.5.
(F–J) Ectopic expression of RCAS-Mmd2 restores expression of glial markers.
(K–O) Ectopic expression of RCAS-Zcchc24 restores ASP (M, N) but not OLP markers (O).
(P–Y) Ectopic expression of RCAS-Apcdd1 rescues ASP (R, S) but not OLP markers (T).
(Z–BB) Ectopic expression of RCAS-Apcdd1-L9R does not rescue NFIA-shRNAi.
(CC–YY) Late-stage rescue reveals similar results; Mmd2 rescues migration of all glial precursor populations (JJ–LL); Zcchc24 and Apcdd1 rescue migration
of ASP (OO, PP, TT, UU) but not OLP (QQ, VV) populations. Boxed areas in (DD), (II), (NN), (SS) represent regions in adjacent sections shown at higher power in
(EE)–(VV).
Quantification methods in (Z)–(BB) and (WW)–(YY) are described in Supplemental Experimental Procedures. The values in (Z)–(BB) are derived from eight
embryos and ten adjacent sections series’ per embryo. For (WW)–(YY), each condition the values represent eight sections from at least five embryos. Error bars
represent SD. Please also see Figure S7.
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precursor populations in the embryonic spinal cord.
That knockdown ofMmd2 resulted in a loss of precursor pop-
ulations without increased cell death suggests that it influences
cell proliferation. To determine whether loss of Mmd2 effects
proliferation, we electroporated the Mmd2-shRNAi (or mutant(O, Q, S) Sox9 and NFIA collaborate to activate the Apcdd1, Mmd2, and Zcchc
experiments performed in triplicate. Error bars represent SD; *p < .007.
(T–CC) NFIA does not rescue loss of Apcdd1 (V, AA),Mmd2 (W, BB), or Zcchc24
Please also see Figures S5 and S6.control) and performed BrdU labeling on chick embryos at E6.
We found that knockdown of Mmd2 results in a 70% decrease
in BrdU incorporation at E6, suggesting that these phenotypes
are the result of decreased proliferation (Figures 6G, 6N, and 6U).
Mmd2 (or PAQR10) contains a putative mitochondrial target-
ing sequence (MTS) and has previously been shown to localize24 promoters. Values presented are the average of a least five independent
(X, CC) in the presence of Sox9-EnR. Arrows denote loss of gene expression.
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Figure 6. Mmd2 Knockdown Results in Decreased Proliferation of Glial Precursors and Respiratory Chain Activity
(A–F) shRNAi knockdown of Mmd2 (A, B), results in decreased expression of all glial markers.
(H–M) Mutant Mmd2-shRNAi does not effect expression of these markers.
(O–T) Ectopic expression of Mmd2 with Mmd2-shRNAi rescues loss of glial markers.
(G, N, U) Reduced BrdU incorporation in Mmd2-shRNAi knockdown (G, U) compared to mutant shRNAi control (N, U).
(V–X) Expression of myc-tagged Mmd2 in U87 cells colocalizes with mitochondrial marker, MitoTracker.
(Y) Knockdown of Mmd2 in chick spinal cord results in decreased activity of respiratory chain complexes II and IV.
Error bars represent SEM. Please also see Figure S8.
Neuron
Sox9 and NFIA Coordinate Gliogenesisto the mitochondria (Go´n˜ez et al., 2008). To confirm these
findings, we overexpressed Myc-tagged Mmd2 in U87 astrocy-
toma cells and found that it localizes to mitochondria (Figures
6V–6X). Because loss of Mmd2 does not appear to influence
cell death (Figure S8), we reasoned that it plays a role in energy
metabolism. To determine whether Mmd2 influences mitochon-
drial oxidative energy metabolism, we performed enzymologic
assays of respiratory chain complexes II–IV and citrate synthase
on E6 chick spinal cord electroporated with Mmd2-shRNAi,
mutant control, and a GFP-only control. Specific knockdown of
Mmd2 resulted in a 50% reduction in the activity of complex
II and IV, compared to mutant and transfection controls, sug-
gesting that oxidative respiration is impaired in the absence of
Mmd2 (Figure 6Y). Together, our developmental and biochem-
ical studies in chick correlate Mmd2 function in glial precursor
proliferation to the activity of respiratory chain complexes II/IV
in the mitochondria.88 Neuron 74, 79–94, April 12, 2012 ª2012 Elsevier Inc.Apcdd1 Promotes ASP Migration
To determine the role of Apcdd1 during gliogenesis, we gener-
ated amutant version that has previously been shown to function
as a dominant negative (Apcdd1-L9R) (Shimomura et al., 2010).
Coexpression of Apcdd1-L9R (herein, L9R) with NFIA-shRNAi
is not able to rescue gliogenesis (Figures 5U–5BB), suggesting
that this mutant functions either as a dominant negative or null
in this system. Overexpression of L9R in the chick spinal cord
did not affect the generation or proliferation of ASP populations
in the VZ at E5 (Figure S8), but analysis at later stages (E9.5)
revealed a 50% decrease in the number of migrating ASPs,
without effecting OLP migration or cell proliferation measured
by PCNA (Figures 7A–7G). Gain-of-function studies with Apcdd1
gave complementing results, where it promoted precocious
migration of ASPs, but not OLPs, and had no effect on PCNA
(Figures 7G–7M). These data indicate that Apcdd1 functions to
specifically promote ASP migration during gliogenesis.
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Figure 7. Apcdd1 Promotes Astrocyte Precursor Migration
(A–F) Overexpression of Apcdd1-L9R inhibits migration of ASP populations at E9.5, without effecting the migration OLP (E) populations or expression of
PCNA (F).
(H–M) Overexpression of Apcdd1 promotes precocious migration of ASP populations at E7, without effecting OLP populations or expression of PCNA (L, M).
(O–T) Expression of Apcdd1 in HeLa cells promotes actin polymerization (P, arrow), while Apcdd1-L9R does not (Q, arrow).
(U) Apcdd1 and Apcdd1-L9R co-IP with Rac1 and cdc42 in HEK293 cells transfected with a flag-tagged version of Apcdd1 and GFP-fusion versions of Rac1 and
cdc42.
(V–AA) cdc42 colocalizes with Apcdd1 at membrane (V–X, arrow), while Apcdd1-L9R colocalization is increased in the cytosol (Y–AA, arrow).
Quantification methods in (G) and (N) are described in Supplemental Experimental Procedures. For each condition, the values represent eight sections from at
least eight embryos. Error bars represent SD. Please also see Figure S8.
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of Apcdd1 overexpression on a cellular level by assessing
F-actin dynamics in vitro. Here we found that overexpression
of Apcdd1 resulted in an increase in F-actin polymerization,
a phenotype associated with cell migration andmotility, whereas
L9R did not (Figures 7M–7R; Le Clainche and Carlier, 2008).
Because assembly of F-actin fibers is associated with Rho-
GTPases (Machesky and Hall, 1997; Nobes and Hall, 1995), we
next investigated whether Apcdd1 can associate with Rho-
GTPases by performing co-IP studies on ectopically expressed,
tagged versions of Apcdd1 and GFP-fusion versions of Rho,
Rac1, or cdc42 in HEK293 cells. We found that both Apcdd1and L9R co-IP with Rac and cdc42, suggesting this association
mediates their respective phenotypes (Figure 7S). The Apcdd1-
L9R mutation disrupts normal membrane localization and so we
next examined intracellular localization of Apcdd1 or L9R with
Rac1 and cdc42 (Shimomura et al., 2010). Coexpression of
Apcdd1withRac1 or cdc42 and subsequent immunolocalization
revealed that Apcdd1 colocalizes with each of these Rho-
GTPases at the cell membrane, whereas L9R colocalization
appears to be mostly cytosolic (Figures 7T–7Y and S8). These
data implicate Apcdd1 function in ASP migration and correlate
this in vivo activity with actin polymerization and association
with Rho-GTPases.Neuron 74, 79–94, April 12, 2012 ª2012 Elsevier Inc. 89
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Here we delineated a transcriptional regulatory cascade that
operates during the initiation of gliogenesis in the developing
spinal cord and identified a unique set of genes that regulate
key aspects of astro-glial precursor physiology. Although analo-
gous transcriptional cascades have been elucidated during
neurogenesis, our studies demonstrate a transcriptional hier-
archy that functions during neural stem cell commitment to the
glial lineage in vivo. In the course of these studies, we found
that key members of this hierarchy, Sox9 and NFIA, physically
associate and collaborate to control induction of glial-specific
genes. Functional studies revealed that a subset of these genes,
Apcdd1 and Mmd2, perform key migratory and metabolic roles
during gliogenesis, respectively. Together, these studies link
the Sox9/NFIA regulatory complex to multiple genetic programs
that regulate the physiology of astro-glial precursors, suggesting
that they have unique metabolic and migratory properties that
distinguish them from their neuronal counterparts.
Regulation of NFIA Induction during the Gliogenic
Switch
Our enhancer screen identified e123 as a regulatory element
whose activity recapitulates the spatial and temporal patterns
of NFIA induction. Analysis of this enhancer revealed that Sox9
is responsible for its activity and controls the induction of NFIA
expression in bothmouse and chick spinal cord. Recently, Notch
signaling has been implicated in the upregulation of NFIA during
astrocyte differentiation in cortical cultures (Namihira et al.,
2009). However, studies on Notch signaling during the gliogenic
switch in the embryonic spinal cord indicate that it does not
result in the induction of NFIA or gliogenesis in vivo (Deneen
et al., 2006; Park and Appel, 2003; Zhou et al., 2001). Thus, regu-
lation of NFIA by Notch may reflect a stage-specific phenom-
enon in differentiated astrocytes or a region-specific mechanism
of regulation (i.e., cortex versus spinal cord). Indeed, regulation
of the proneuronal gene neurogenin 2 (ngn2) is both domain
and region specific (Henke et al., 2009; Novitch et al., 2001; Stoy-
kova et al., 2000; Yun et al., 2001). Alternatively, given its well-
established role in maintaining the progenitor pool, Notch may
function as a permissive factor rather than an instructive cue
for NFIA induction in vivo (Androutsellis-Theotokis et al., 2006;
Imayoshi et al., 2010; Shimojo et al., 2008).
Although Sox9 directly controls NFIA induction, it is eventually
expressed, albeit in a delayed and reduced manner, in the
absence of Sox9. This raises the question of what other factors
contribute to the regulation of NFIA induction or expression
during gliogenesis. One possibility is partial compensation by
other Sox proteins. Several Sox proteins are expressed in spinal
cord VZ populations during gliogenesis and play active roles in
glial differentiation (Bylund et al., 2003; Graham et al., 2003; Stolt
et al., 2002, 2005; Stolt andWegner, 2010). Another possibility is
that Sox9 controls the timing of NFIA induction but other factors
are responsible for maintaining its expression during later stages
of gliogenesis, and in the absence of Sox9, these factors are
able to partially compensate for its absence. Sox proteins have
been implicated in stage-specific gene regulation during lens
development, where Sox2 controls expression of N-cadherin in90 Neuron 74, 79–94, April 12, 2012 ª2012 Elsevier Inc.preplacode ectoderm, and later in development, regulation of
N-cadherin becomes dependent upon Pax6 (Smith et al.,
2009). An analogous mechanism may be controlling NFIA
expression during astro-glial development.
Another key consideration in our understanding of the tran-
scriptional mechanisms controlling the induction of NFIA is the
role of epigenetics. Chromatin-modifying factors, PcG genes
Ring1b and Ezh2, have been implicated in the repression of
neurogenesis, a key process in the gliogenic switch, in the
embryonic cortex, and DNA methylation has been implicated in
regulating the expression of GFAP during astrocyte differentia-
tion (Fan et al., 2005; Hirabayashi et al., 2009; Takizawa et al.,
2001). Future studies will be aimed at examining the link between
epigenetic modifiers and NFIA induction.
Sox9 and NFIA Complex Formation—Managing Sox9’s
Diverse Roles
Biochemical studies demonstrate that NFIA and Sox9 physically
associate and collaborate to induce the expression of a subset
of genes just after the initiation of gliogenesis. Given that Sox9
function is associated with neural stem cell maintenance, initia-
tion of gliogenesis, and various aspects of glial differentiation
during CNS development, its interaction with NFIA may mediate
a subset of these diverse roles. Although Sox9 induction of NFIA
may trigger the generation of glial fates, it does not result in
a loss of neurogenic potential from these populations, as Sox9
expression is required at these stages for neurosphere forma-
tion in vitro, and NFIA is not sufficient to suppress neurogenesis
(Deneen et al., 2006; Scott et al., 2010). Therefore, we propose
a model whereby Sox9 function during the gliogenic switch
evolves frommaintaining neural stem cells and initiating gliogen-
esis (E10.5–E11.5) to promoting glial lineage progression
(E11.5–E12.5) by controlling a set of genes that contribute to
early gliogenesis (Figure 8). This shift in Sox9 function during
glial lineage progression is facilitated by a feedforward mecha-
nism, where Sox9 induces NFIA expression during glial initiation
and subsequently associates with NFIA to drive lineage pro-
gression. Hence, Sox9 coordinates glial initiation and glial
lineage progression via regulation and association with NFIA,
respectively.
Our rescue analysis of targets of the Sox9/NFIA complex
found that these genes restore panglial or ASP-specific identity
during gliogenesis. The role of this complex in ASP formation is
supported by specific defects at later developmental stages in
astrocyte differentiation in both Sox9 and NFIA knockout mice
(Deneen et al., 2006; Stolt et al., 2003). That this complex
appears to influence ASP development raises the question of
whether it also has a specific role in oligodendrocyte precursor
(OLP) development. Given that both NFIA and Sox9, and the
targets we identified, are also expressed in OLPs, it is possible
that a subset of their targets specifically contribute to OLP
development. Alternatively, if the Sox9/NFIA complex plays an
ASP-specific role, it is likely that Olig2 interferes with the ability
of this complex (or its targets) to activate ASP-specific genetic
programs in OLPs. Indeed, Olig2 is a known antagonist of astro-
cyte development and has been shown to physically interact
with NFIA and inhibit its ability to promote astrocyte differentia-
tion (Deneen et al., 2006; Hochstim et al., 2008).
AB
Figure 8. Sox9 and NFIA Comprise a Regulatory Hierarchy that
Operates during Multiple Phases of Early Gliogenesis
(A) Sox9 induction of NFIA regulates the initiation of gliogenesis. Based on the
timing of the induction patterns of Sox9 and NFIA, this event occurs between
E10.5 and E11.5 and represents the initiative steps of neural stem cell
commitment to the glial lineage. It remains to be determined whether Sox9
initiation of gliogenesis can be dissociated from its role in NSC maintenance,
represented by the double-headed arrow.
(B) The Sox9/NFIA complex controls the induction of Apcdd1 and Mmd2,
which function to promote ASP migration and energy metabolism, respec-
tively. Based on the timing of Apcdd1 and Mmd2 induction (and other candi-
dates described in Figure 3) and their coregulation by Sox9 and NFIA, these
events occur between E11.5 and E12.5 and represent a distinct step in early
gliogenesis, which we termed formative gliogenesis.
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In the course of these studies, we utilized temporal profiling of
neural stem cell populations and identified a subset of genes
that are specifically induced between E11.5 and E12.5, just after
the initiation of gliogenesis. Given that the paucity of reliable
markers of early gliogenesis has hindered the study of these
formative stages of gliogenesis and the intermediate stages of
astro-glial development in vivo, this group of genes represents
a unique set of markers that designates such stages of the glial
lineage and may facilitate these studies. Indeed, there has
been considerable effort to identify newmarkers of glial lineages,
especially those that specifically mark astrocytes and subpopu-
lations of astrocytes (Cahoy et al., 2008; Garcia et al., 2010;
Hochstim et al., 2008; Yang et al., 2011).
Comparison of the genes we found to be induced after the
initiation of gliogenesis with a transcriptome database of astro-
cyte and oligodendrocyte populations from the brain found
that Hod-1 and Fgfbp3 are specifically expressed in astrocytes(Cahoy et al., 2008). Recent studies found that Ndrg2 is ex-
pressed in astrocyte populations in the adult mouse brain
(Shen et al., 2008). These observations suggest that these genes
are expressed in multiple regions of the CNS (i.e., brain and
spinal cord) and throughout astrocyte lineage development
and, consequently, may be general markers of astrocytes. Func-
tionally, both Hod-1 and Ndrg2 are incapable of restoring ASPs
or OLPs in the absence of NFIA, suggesting that they may
contribute to later stages of ASP development (data not shown).
Consistent with this, Ndrg2 expression has been linked to prolif-
erating astrocytes in vitro (Shen et al., 2008).
Role of Apcdd1 and Mmd2 in Glial Development
Functional studies in the embryonic chick spinal cord demon-
strate that Apcdd1 specifically rescues ASP populations,
whereas Mmd2 rescues both ASP and OLP populations in the
absence of NFIA. These data, coupled with our observations
that Sox9 and NFIA coregulate their expression, indicate that
Apcdd1 and Mmd2 are functionally downstream of Sox9 and
NFIA in the gliogenic cascade. Functional analysis of both genes
revealed that they contribute to key physiological processes
germane to glial precursor maintenance and differentiation.
Mmd2 (or PAQR10) contains a putative MTS and localizes to
themitochondria, though its precise function there has remained
undefined (Go´n˜ez et al., 2008). We found that knockdown of
Mmd2 in the chick spinal cord resulted in reduced numbers of
glial progenitor populations, because of a decrease in their pro-
liferative capacity. Alternatively, it is also possible that these
changes in proliferation are a consequence of direct changes
in cell fate; future studies will be aimed at delineating these
models of Mmd2 function. Biochemical analysis revealed that
loss of Mmd2 in the chick spinal cord results in decreased
activity of respiratory chain complexes II and IV, thus correlating
the proliferation of glial progenitors with energy metabolism.
Indeed, electron transport chain function has previously been
linked to cell cycle regulators and proliferation; therefore, it will
be important to decipher the relationship between complex
II/IV, cell proliferative mechanisms, and glial precursor biology
(Mandal et al., 2010; Schauen et al., 2006). Moreover, that
Mmd2 appears to regulate energy metabolism via complex
II/IV and is induced just after glial specification suggests that
glial precursors have unique energy and/or metabolic require-
ments that are distinct from neural stem cells and committed
neuronal progenitors. It is likely that each of these cell popula-
tions have unique metabolic profiles that reflect their biology
and/or impending lineage commitments; indeed, neurons,
astrocytes, and oligodendrocytes each have distinct metabolic
requirements. Interestingly, the timing of cardiac myocyte
differentiation has been linked to mitochondria maturation and
function, indicating that metabolic function participates in
lineage development (Hom et al., 2011). Therefore, in the future
it will be important to identify distinct metabolic features of these
precursor populations and to further delineate how these
processes are coordinated with transcriptional cascades that
specify their identity.
Apcdd1 is a membrane-bound glycoprotein that can inhibit
canonical Wnt signaling through association with Wnt receptor
complexes, though its exact role during spinal cord developmentNeuron 74, 79–94, April 12, 2012 ª2012 Elsevier Inc. 91
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studies revealed a mild effect of Apcdd1-L9R on proliferation
and specification during neurogenesis, phenotypes that we did
not observe during gliogenesis (Figures 7 and S8), probably
reflecting stage-specific effects of Apcdd1-L9R. Our studies
indicate that Apcdd1 plays a key role in the migration of ASP
populations, probably through an association with Rho-
GTPases. The observation that Apcdd1 can influence Wnt re-
ceptor complexes, coupled with the role of noncanonical Wnt
signaling in cell migration and regulation of Rho-GTPases,
suggest a model whereby Apcdd1 could function to promote
ASP migration via noncanonical Wnt signaling (Schlessinger
et al., 2009). That L9R overexpression does not effect the gener-
ation of ASP populations in the VZ suggests thatApcdd1 is either
not necessary for the generation of these populations or func-
tions through other mechanisms. Alternatively, the epithelial to
mesenchymal transition (EMT) has been shown to promote
migration and the acquisition of progenitor-like states (Mani
et al., 2008; Acloque et al., 2009). Therefore, one possibility is
that Apcdd1 activates an EMT program that is sufficient to
restore ASP populations in the absence of NFIA. Nevertheless,
a more comprehensive understanding of signaling pathways
associated with Apcdd1 function will provide further insight
into its role during astro-glial development.
EXPERIMENTAL PROCEDURES
Chick and Mouse Experiments
Expression constructs were cloned into the RCAS(B) (Morgan and Fekete,
1996) or pCIG vector (Megason and McMahon, 2002). Constructs were
injected into the chick spinal cord at stage HH13–HH15 (E2). See Supple-
mental Information for construct information. Electroporation was carried out
with a BTX Electro Square Porator (Momose et al., 1999). NFIA+/ (das Neves
et al., 1999), Sox9fl/fl (Akiyama et al., 2002), and nestin-cre (Betz et al., 1996)
were used. The Sox9fl/fl mice were intercrossed with the nestin-cre mice to
generate Sox9fl/fl;nestin-cre and Sox9fl/+;nestin-cre mice. Care of all animals
and procedures were approved by the Baylor College of Medicine Institutional
Animal Care and Use Committee.
ChIP and Immunoprecipitation
Mouse E12.5 spinal cord was dissected, dissociated, and processed for ChIP
assays. Similarly, the electroporated chick spinal cords was dissected and
used in ChIP assays. See Supplemental Information for details and ChIP
primer sequences. Co-IP was performed by combining five E12.5 mouse
spinal cords per experiment. Spinal cords were homogenized and the cell
lysates were subject to immunoprecipitation with a specific antibody or IgG
control and protein G agarose beads. See Supplemental Information for
additional information.
In Situ Hybridization and Immunostaining
In situ hybridization on frozen mouse and chicken embryos was performed as
previously described (Deneen et al., 2006). Mouse and chick tissue was fixed
in 4% paraformaldehyde. The following probes were used for in situ hybridiza-
tion: cGLAST, cFGFR3, cFABP7, cPDGFRa, mGLAST, cApcdd1, cMmd2, and
cZcchc24. DNA to generate probes for the candidate gene in situs in Figures 3
and S4 was purchased from Open Biosystems. See Supplemental Information
for probe and antibody information.
Reporter Assays and qPCR
Mouse Apcdd1, Mmd2, and Zcchc24 promoter fragments were generated
from mouse genomic DNA. Each promoter was cloned into a pGL3-basic
vector. HEK293 cell line was transfected with reporter constructs and
CMV-b-galactosidase vector and harvested, and cell lysate was mixed with92 Neuron 74, 79–94, April 12, 2012 ª2012 Elsevier Inc.luciferin to measure luciferase activity. For normalization of transfection
efficiency, b-galactosidase was measured by the absorbance at 430 nm. Total
RNA was isolated from E12.5 mouse spinal cord with a RNeasy mini isolation
kit (QIAGEN). Quantitative RT-PCR was performed with PerfeCta SYBR Green
Fast Mix (Quanta Biosciences) and a LightCycler 480 (Roche). See Supple-
mental Information for primer sequences used in these studies.
Analysis of Respiratory Chain Complexes
For enzymologic assays of respiratory chain complexes I–IV and citrate
synthase, individual dissected chick embryonic spinal cords were lysed by
sonication and spectrophotometric kinetic assays were performed with a
monochromator microplate reader (Tecan M200). Complex II (succinate
dehydrogenase), Complex III (ubiquinol: cytochrome c oxidoreductase),
Complex IV (cytochrome c oxidase), and Citrate synthase activities were
measured as described (Graham et al., 2010). Activities were calculated as
nmol/min/mg protein, normalized to citrate synthase activity, and expressed
as a percentage of wild-type activity. For each group, spinal cords from six
embryos were tested.
In Vitro Immunolocalization
For mitochondria localization, human U87 cells were transfected with myc-
tagged Mmd2 plasmid with lipofectamine. After 2 days transfection, cells
were stained with 100 nM MitoTracker (Molecular Probes) and then fixed for
immunostaining to detect Myc expression. For actin studies, HeLa cells
were transfected with Flag-tagged Apcdd1 wild-type or mutant (L9R). One
day after trasfection, cells were moved to serum-free medium for 18 hr, fixed,
and immunostained with Flag- and Alexa 488-conjugated phalloidin anti-
bodies (Molecular Probes).
Bioinformatics
NIH Vista and ECR browser genomic alignment programs were used to
compare 100 kb upstream of the mouse and chick NFIA gene. Upon isolation
from chick genomic DNA, enhancer fragments were cloned into Topo2.1
vector, followed by subcloning of GFP with a minimum TATA box. Chick
e123 genomic location: chromosome8: 27803349-27804949; mouse e123
genomic location: chromosome4: 97385017-97386617.
Analysis of microarray data was performed with Rosetta Resovler software
as previously described (Hochstim et al., 2008). Please also see Table S1. We
used the MAPPER search engine and database to identify putative Sox9 and
NFIA binding sites (Marinescu et al., 2005). For details of screening procedure,
please see Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and one table and can be found with this article online at
doi:10.1016/j.neuron.2012.01.024.
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